Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine for binge-eating disorder neural mechanisms study
ACTRN12618000623291Phase 4Recruiting
- Sponsor
- University of Sydney
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lisdexamfetamine in binge eating disorder (BED) (2 arms), sponsored by University of Sydney. Started May 2018; status: recruiting.
02
Drugs
lisdexamfetamine
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on ACTRN12618000623291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000623291.